ArticleMediators of inflammation2020
Cangfudaotan Decoction Alleviates Insulin Resistance and Improves Follicular Development in Rats with Polycystic Ovary Syndrome via IGF-1-PI3K/Akt-Bax/Bcl-2 Pathway.
Article in Mediators of inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.Frontiers in endocrinology · 2022Trial
- Orchestrating Ovarian Dysfunction- The Role of Programmed Cell Death in PCOS.Cell biochemistry and biophysics · 2026Article
- Review
- Article
- The association between triglyceride glucose-body mass index and live birth outcomes in women with clinical pregnancy after frozen-thawed embryo transfer: a cohort study.BMC pregnancy and childbirth · 2026Article
- Unveiling the role of the PI3K/Akt signaling pathway in follicular development and non-malignant ovarian dysfunction: a comprehensive review.Journal of ovarian research · 2026Review
- Article
- Obacunone alleviated the development of polycystic ovary syndrome via inhibiting STAT3 phosphorylation.Journal of ovarian research · 2025Article
- Evaluation of representativeness and sustainability of PCOS rat models induced by letrozole with or without high-fat diet.Scientific reports · 2025Article
- Study on the effects of Mogroside V in inhibiting NLRP3-mediated granulosa cell pyroptosis and insulin resistance to improve PCOS.Journal of ovarian research · 2025Article
- Mechanisms of traditional Chinese medicine regulating polycystic ovary syndrome through gut microbiota: a review.Frontiers in endocrinology · 2025Review
- Research progress on the pathogenesis, clinical impact, and traditional Chinese medicine treatment of polycystic ovary syndrome complicated by insulin resistance.Frontiers in pharmacology · 2025Review
- The Beneficial Effects ofInternational journal of molecular sciences · 2024Article
- Inferring Causal Relationships Between Metabolites and Polycystic Ovary Syndrome Using Summary Statistics from Genome‑Wide Association Studies.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Inhibition of FoxO1 alleviates polycystic ovarian syndrome by reducing inflammation and the immune response.Functional & integrative genomics · 2024Article
- Effects of natural products on polycystic ovary syndrome: From traditional medicine to modern drug discovery.Heliyon · 2023Article
- Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome.Cells · 2023Review
- hUMSC transplantation restores follicle development in ovary damaged mice via re-establish extracellular matrix (ECM) components.Journal of ovarian research · 2023Article
- Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder prevalent in females of reproductive age; insulin resistance (IR) is the major pathogenic driver. Pharmacology is a basic option for PCOS therapy; traditional Chinese medicine (TCM), as a significant part of complementary and alternative medicine, has a long history in the clinical management of PCOS. Cangfudaotan decoction (CFD) has been used clinically for gynaecological diseases especially PCOS. In this study, first, chemical components in CFD were clarified using UPLC-Q/TOF-MS analysis. Then, an animal model of PCOS was established, granular cells were also isolated from the rats with PCOS, and CFD was administrated at different dosages in PCOS rats and granular cells, to investigate the therapeutic effect and mechanisms of CFD for PCOS treatment. The result showed that CFD treatment is effective in PCOS rats and granulosa cells. CFD was able to improve IR, restore the serum hormone levels, inhibit the inflammatory cytokines in PCOS rat, and alleviate ovary morphological injury and apoptosis in PCOS rats. In granulosa cells of PCOS, the result showed that the cell viability was improved, and cell apoptosis was inhibited after CFD administration. Further experiments suggested that CDF improves IR, follicular development, cell apoptosis, and inflammatory microenvironment, and this was associated to the regulation of IGF-1-PI3K/Akt-Bax/Bcl-2 pathway-mediated gene expression. Given that CFD sufficiently suppresses insulin resistance and improves follicular development in this study, exploring these mechanisms might help to optimize the therapeutic treatment of CFD in PCOS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.